Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4392-4401
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4392
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4392
PD-1 inhibitor | CR | PR | SD | PD | P value |
Tislelizumab | 2 (14.3) | 5 (35.7) | 4 (28.6) | 3 (24.1) | 0.927 |
Sintilimab | 1 (5.9) | 10 (58.8) | 5 (29.4) | 1 (5.9) | |
Camrelizumab | 6 (13.3) | 17 (37.8) | 14 (31.1) | 8 (17.8) | |
Toripalimab | 4 (14.3) | 12 (42.9) | 8 (28.5) | 4 (14.3) |
- Citation: Yang H, Qiu GP, Liu J, Yang TQ. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(11): 4392-4401
- URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4392.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4392